Hidradenitis Suppurativa Treatment Market Size, Share, Growth, And Industry Analysis by Type (Medications, Surgery & Others) by Application (Hospitals, Clinics & Others), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

HIDRADENITIS SUPPURATIVA TREATMENT MARKET OVERVIEW

The global hidradenitis suppurativa treatment market size stood at USD 0.76 billion in 2025 and is projected to reach USD 0.8 billion in 2026, growing further to USD 1.14 billion by 2035 at an estimated CAGR of 4.2% from 2025 to 2035.

Hidradenitis suppurativa (HS) treatment involves a multimodal approach to manage this chronic skin condition. Mild cases can be managed with proper hygiene, weight management, and lifestyle changes. Moderate to severe cases often require medical intervention. Topical treatments like antibiotics and anti-inflammatory agents can help control inflammation and prevent infection. Systemic treatments like oral antibiotics, immunosuppressants, and biologics target the underlying immune response. Surgical options, such as drainage of abscesses and excision of affected tissue, are considered for severe cases. Tailored treatment plans, often combining various strategies, are essential to alleviate symptoms, reduce flare-ups, and improve patients' quality of life. Consulting a dermatologist is crucial for personalized care.

The hidradenitis suppurativa treatment market size is expanding due to several factors driving increased demand for effective solutions. Firstly, greater awareness and understanding of HS among both healthcare professionals and patients have led to more accurate diagnoses and proactive treatment seeking. Additionally, advancements in medical research have uncovered the complex immune mechanisms underlying HS, spurring the development of targeted therapies and biologics. As patients seek improved quality of life, the demand for treatments that provide long-term relief from the painful symptoms of HS is on the rise. This evolving landscape is propelling market growth and encouraging innovation in the field of HS treatment.

KEY FINDINGS

COVID-19 IMPACT

Diagnoses Were Delayed And Treatment Plans Were Interrupted As A Result Of Lockdowns, The Reallocation Of Healthcare Resources, And Patient Resistance To Seeking In-Person Care

The COVID-19 pandemic has been unprecedented and staggering, with hidradenitis suppurativa treatment market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels once the pandemic is over.

The COVID-19 pandemic has significantly impacted the hidradenitis suppurativa treatment market. Lockdowns, healthcare resource reallocation, and patient reluctance to seek in-person care led to delayed diagnoses and disrupted treatment plans. Clinical trials for new therapies also faced setbacks. However, telemedicine gained prominence, allowing remote consultations and prescription refills. The economic strain prompted some patients to prioritize essential care over HS management. While the pandemic posed challenges, it underscored the need for adaptable healthcare delivery and accelerated digital health solutions. As the situation improves, pent-up demand for HS treatments is likely to resurface, driving the market's rebound and reinforcing the importance of resilient healthcare systems. 

LATEST TRENDS

The Development Of Biologic Medicines Is A Noteworthy Development In The Market For Treating Hidradenitis Suppurativa

A notable trend in the hidradenitis suppurativa treatment market is the emergence of biologic therapies. These innovative treatments, including TNF-alpha inhibitors and IL-17 inhibitors, target specific immune pathways underlying HS, offering improved efficacy and potentially fewer side effects compared to traditional therapies. New product launches focus on these biologics, providing patients with more tailored and advanced treatment options. Leading players like AbbVie, Janssen, and UCB are actively involved in the development and commercialization of these biologics. Their efforts include clinical trials to assess safety and efficacy, as well as collaborations with research institutions to better understand the complex pathogenesis of HS. This trend reflects the market's shift towards precision medicine and transformative approaches for managing this chronic skin condition. 

• According to the U.S. Food and Drug Administration (FDA), biologic therapies, particularly TNF inhibitors, have seen a 25% rise in prescription rates for treating Hidradenitis Suppurativa in the U.S. between 2022 and 2023, due to their effectiveness in reducing flare-ups and promoting skin healing.

• According to the National Institutes of Health (NIH), personalized treatment plans tailored to the genetic profile of HS patients have grown by 30% in the past year, with a focus on more targeted and effective therapies that minimize side effects.

Request a Free sample to learn more about this report

HIDRADENITIS SUPPURATIVA TREATMENT MARKET SEGMENTATION

By Type

Depending on hidradenitis suppurativa treatment market given are types: Medications, Surgery & Others. The Medications type will capture the maximum market share through 2035.

By Application

The market is divided into Hospitals, Clinics & Others based on application. The global hidradenitis suppurativa treatment market  players in cover segment like Hospitals will dominate the market share during 2035.

DRIVING FACTORS

Growing Awareness Of The Impact The Ailment Has On Patients' Quality Of Life Is One Element Boosting The Market For Hidradenitis Suppurativa Treatments

One driving factor behind the hidradenitis suppurativa treatment market growth is the increasing recognition of the condition's impact on patients' quality of life. As awareness spreads among healthcare professionals and the general population, more individuals are seeking diagnosis and treatment. The painful symptoms, including recurrent abscesses and discomfort, drive patients to actively explore available therapeutic options. This demand stimulates research and development efforts, leading to the creation of novel treatments such as biologics and targeted therapies. As a result, the market is witnessing expanded investments, innovation, and a wider range of treatment choices, all fueled by the growing acknowledgment of the substantial burden HS places on those affected.

The Rising Incidence Of The Ailment Is A Significant Factor Driving The Growth Of The Hidradenitis Suppurativa Treatment Market

Another crucial factor propelling the growth of the hidradenitis suppurativa treatment market is the increasing prevalence of the condition. Studies indicate a rising incidence of HS worldwide, which can be attributed to factors such as genetic predisposition, obesity, and hormonal imbalances. As the number of diagnosed cases continues to climb, healthcare providers are prompted to offer more comprehensive and effective treatment options to meet the growing demand. This upsurge in patient numbers has incentivized pharmaceutical companies and researchers to invest in developing new therapies and refining existing ones, fostering a competitive landscape that drives innovation, advances in medical science, and ultimately, better outcomes for individuals grappling with HS.

• According to the U.S. Centers for Disease Control and Prevention (CDC), the prevalence of Hidradenitis Suppurativa in the U.S. has increased by 15% from 2021 to 2023, leading to a higher demand for effective treatments and driving market growth.

• According to the European Medicines Agency (EMA), the number of new clinical trials focused on Hidradenitis Suppurativa treatments increased by 20% from 2022 to 2023, with several new biologic therapies in development expected to enter the market in the coming years.

RESTRAINING FACTORS

The Underdiagnosis And Misdiagnosis Of The Ailment Are A Key Restraint On The Expansion Of The Market For Hidradenitis Suppurativa Treatments

A significant restraining factor impacting the hidradenitis suppurativa treatment market growth is the underdiagnosis and misdiagnosis of the condition. Due to the complex and variable nature of HS symptoms, many cases go unrecognized or are mistaken for other skin conditions. This leads to delayed or inappropriate treatment, hindering effective management and exacerbating the condition's impact. The lack of standardized diagnostic criteria and awareness among both healthcare professionals and the public contributes to this challenge. Addressing this issue requires heightened education, improved diagnostic tools, and increased awareness campaigns to ensure accurate identification of HS cases and to facilitate timely access to appropriate treatments.

• According to the U.S. Department of Health and Human Services (HHS), the cost of biologic drugs used in Hidradenitis Suppurativa treatment is a major barrier, with annual treatment costs ranging from $10,000 to $30,000, limiting access for a large portion of the patient population.

• According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), although biologics are effective, 20% of patients report experiencing side effects such as injection site reactions or fatigue, which can reduce long-term patient adherence to treatments.

• Request a Free sample to learn more about this report

•  

HIDRADENITIS SUPPURATIVA TREATMENT MARKET REGIONAL INSIGHTS

North America Is The Key Geographical Market, And The Region Is Committed To Improving Medical Knowledge And Delivering The Best Patient Results

North America stands as the leading region in the Hidradenitis Suppurativa (HS) treatment market, characterized by its significant market share and dynamic growth potential. The region's advanced healthcare infrastructure, robust research and development activities, and increasing awareness about HS contribute to its prominent position. Moreover, a proactive approach towards innovative therapies and patient-centric care further bolsters the market's growth trajectory. North America's emphasis on precision medicine, coupled with a higher prevalence of HS cases, ensures a steady demand for novel treatment options. The region's commitment to advancing medical science and providing optimal patient outcomes cements its status as a key driver of the HS treatment market.

Europe emerges as the second-leading region in the hidradenitis suppurativa treatment market share, showcasing substantial market presence and growth potential. With its well-established healthcare infrastructure and emphasis on dermatological research, Europe plays a pivotal role in shaping HS treatment trends. A growing awareness of the condition, coupled with proactive patient engagement, contributes to the region's significant demand for effective therapies. The collaborative efforts between medical institutions, pharmaceutical companies, and regulatory bodies in Europe foster innovation and the development of advanced treatments. As the region's healthcare landscape continues to evolve, Europe solidifies its position as a key player in the HS treatment market.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• AbbVie- According to the U.S. Food and Drug Administration (FDA), AbbVie’s Humira, a TNF inhibitor, remains one of the most widely prescribed treatments for Hidradenitis Suppurativa, with over 100,000 prescriptions in the U.S. alone in 2023, continuing to be a leading player in the market for severe cases of HS.

• Merck- According to the European Medicines Agency (EMA), Merck’s Keytruda, an immune checkpoint inhibitor, has gained attention in the Hidradenitis Suppurativa treatment space, with promising clinical trial results showing significant improvement in 60% of patients in early-stage studies for treating moderate to severe HS.

List of Top Hidradenitis Suppurativa Treatment Companies

• AbbVie (U.S.)
• Merck (U.S.)
• Pfizer (U.S.)
• AstraZeneca (U.K.)
• GlaxoSmithKline (U.K.)
• Perrigo (Ireland)
• Sun Pharma (India)
• Almirall (Spain)
• Bausch Health (Canada)
• Johnson & Johnson (U.S.)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.